Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1680-1687

  Reichardt, P ^a   Blay, J Y ^b   Gelderblom, H ^c   Schlemmer, M ^d   Demetri, G D ^e   Bui nguyen, B ^f   Mcarthur, G A ^g   Yazji, S ^h   Hsu, Y ^h   Galetic, I ^h   Rutkowski, P ⁱ  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b UNIVERSITÉ LYON 1   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f INSTITUT BERGONIÉ   (France)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Gastrointestinal stromal tumors; GIST; Imatinib; Nilotinib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; NILOTINIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION;

EID: 84864293774     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr598     Document Type: Article

References (32)

1. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma v1.2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (5 January 2012, date last accessed).
3. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
4. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
5. Verweij J, Van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-2011.
6. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
7. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113.
8. Gastrointestinal Stromal Tumor Meta-analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247-1253.
9. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
10. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
11. Manley PW, Drueckes P, Fendrich G et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804: 445-453.
12. Cullinane C, Natoli A, Hui Y et al. Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Mol Cancer Ther 2010; 9: 1461-1468.
13. Crossman LC, Druker BJ, Deininger MW et al. hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133-1134.
14. Prenen H, Guetens G, De Boeck G et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006; 77: 11-16.
15. Thomas J, Wang L, Clark RE et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745.
16. White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704.
17. Burger H, van Tol H, Brok M et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005; 4: 747-752.
18. Hamada A, Miyano H, Watanabe H et al. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003; 307: 824-828.
19. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
20. Demetri GD, Casali PG, Blay JY et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009; 15: 5910-5916.
21. Montemurro M, Schoffski P, Reichardt P et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009; 45: 2293-2297.
22. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
23. Tanaka C, Yin OQ, Sethuraman V et al. Clinical pharmacokinetics of the BCRABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010; 87: 197-203.
24. Choi H Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005; 7: 307-311.
25. Hong X, Choi H, Loyer EM et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006; 26: 481-495.
26. Le Cesne A, van Glabbeke M, Verweij J et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27: 3969-3974.
27. Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-1764.
28. Therasse P, Eisenhauer EA, Verweij J RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031-1039.
29. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
30. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
31. ClinicalTrials.gov. Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1). (5 January 2012, date last accessed).
32. Casali PG, Joensuu H, Martin Broto J et al. Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol 2010; 28 Suppl: 7s (Abstr TPS332).